News
Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...
In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?
This was the stock's second consecutive day of losses.
Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...
Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...
Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.
This trial evaluated the safety and efficacy of the combination of Regeneron’s Lynozyfic (linvoseltamab), a B-cell maturation ...
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback